---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002085"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T01:53:47.427378+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rigel prelim Q4 2023 total revenue ~$35.7M; TAVALISSE record $25.7M; MD Anderson deal $15M

## Summary
- Prelim Q4 total revenue ~$35.7M: TAVALISSE net sales $25.7M (record), REZLIDHIA $3.9M.
- Full-year 2023 net product sales $104.3M (+36% YoY); cash & investments $56.9M at year-end.
- Strategic collaboration with MD Anderson to advance REZLIDHIA in AML and other cancers; $15M in milestones over 5 years.
- Collaboration with CONNECT for Phase 2 trial of REZLIDHIA in IDH1-mutant glioma; Rigel funding up to $3M.
- Phase 1b trial of R289 (IRAK1/4 inhibitor) in lower-risk MDS currently enrolling third cohort.

## SEC filing metadata
- accession: 0001104659-24-002085
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465924002085/0001104659-24-002085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465924002085/tm242328d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002085
- JSON: https://secwatch.observer/filing/0001104659-24-002085.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002085.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $35.7 million.
  - Period: fourth quarter and fiscal year ended December 31, 2023
  - Revenue: $35.7 million
  - Result: preliminary results
  source text: --- EX-99.1 2 tm242328d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update · Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million · Strategic alliance with MD Anderson to advance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465924002085/0001104659-24-002085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.